Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul;62(7):711-20.
doi: 10.1007/s00011-013-0626-z. Epub 2013 May 7.

Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages

Aino Salminen  1 , Pirkko J Pussinen, Jeffrey B Payne, Julie A Stoner, Matti Jauhiainen, Lorne M Golub, Hsi-Ming Lee, David M Thompson, Timo Sorsa
Affiliations
Randomized Controlled Trial

Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages

Aino Salminen et al. Inflamm Res. 2013 Jul.

Abstract

Objective: Subantimicrobial-dose doxycycline (SDD) treatment has been reported to reduce the severity of chronic inflammation and to increase serum high-density lipoprotein cholesterol. In a double-blind, placebo-controlled clinical trial, we determined whether SDD affects the ability of serum to facilitate cholesterol removal from macrophages.

Methods: Forty-five postmenopausal osteopenic women with periodontitis were randomly assigned to take placebo (n = 26) or doxycycline hyclate (20 mg, n = 19) tablets twice daily for 2 years. Serum samples were collected at baseline, 1-, and 2-year appointments. The cholesterol efflux capacity of serum from cultured human macrophages (THP-1) was measured.

Results: SDD subjects demonstrated a significant increase in serum-mediated cholesterol efflux from macrophages at both time points compared to baseline (p < 0.04 for each). Mean cholesterol efflux levels over the first year of follow-up were 3.0 percentage points (unit change) higher among SDD subjects compared to placebo subjects (p = 0.010), while there was no significant difference in 2-year changes. There were no significant differences in the changes of apolipoprotein A-I, apolipoprotein A-II, or serum amyloid A levels between the groups.

Conclusions: Our results suggest that SDD treatment may reduce the risk of cardiovascular disease in this patient group by increasing the cholesterol efflux capacity of serum.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. The effect of SDD on the cholesterol efflux capacity of serum during the two-year clinical trial
The efflux capacity of serum samples was measured by incubating acLDL-loaded macrophages in the presence of 1% serum. Cholesterol efflux was calculated as a percentage of [3H]cholesterol released into the medium of the total [3H]cholesterol in the medium and the cells. The efflux capacity of each serum sample was calculated as a mean of three incubations. The number of subjects was 26 in the placebo group and 19 in the SDD group a p-value for 1-year change when comparing between SDD and placebo b p-value for 2-year change when comparing between SDD and placebo
See this image and copyright information in PMC

References

    1. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of Periodontitis in Adults in the United States: 2009 and 2010. J Dent Res. 2012;91:914–920. doi: 10.1177/0022034512457373. - DOI - PubMed
    1. Lockhart PB, Bolger AF, Papapanou PN, Osinbowale O, Trevisan M, Levison ME, et al. Periodontal Disease and Atherosclerotic Vascular Disease: Does the Evidence Support an Independent Association?: A Scientific Statement From the American Heart Association. Circulation. 2012;125:2520–44. doi: 10.1161/CIR.0b013e31825719f3. - DOI - PubMed
    1. Loos BG, Craandijk J, Hoek FJ, Werteim-van Dillen PM, van der Velden U. Elevation of Systemic Markers Related to Cardiovascular Diseases in the Peripheral Blood of Periodontitis Patients. J Periodontol. 2000;71:1528–1534. doi: 10.1902/jop.2000.71.10.1528. - DOI - PubMed
    1. Joshipura KJ, Wand HC, Merchant AT, Rimm EB. Periodontal Disease and Biomarkers Related to Cardiovascular Disease. J Dent Res. 2004;83:151–5. doi: 10.1177/154405910408300213. - DOI - PubMed
    1. Marcaccini AM, Novaes AB, Jr, Meschiari CA, Souza SL, Palioto DB, Sorgi CA, Faccioli LH, Tanus-Santos JE, Gerlach RF. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. Clin Chim Acta. 2009;409:117–22. doi: 10.1016/j.cca.2009.09.012. - DOI - PubMed

Publication types